LIVN — LIVANOVA PLC (Healthcare >> Medical Devices)
LIVN FAQ
What is LIVN's P/E ratio?
LIVANOVA PLC (LIVN) currently trades at a P/E ratio of 38.35.
What is LIVN's ROE?
LIVANOVA PLC reports a Return on Equity (ROE) of 8.84%.
What is LIVN's dividend yield?
LIVANOVA PLC offers a dividend yield of 0.00%.
What is LIVN's Deepscope Quality Score?
Deepscope rates LIVN's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LIVN?
Deepscope's AI Timing Score for LIVN is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LIVN belong to?
LIVANOVA PLC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange.
|
USD 77.17
Price
2.37
(3.17%)
Day Change
|
|
|---|
LIVN, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 77.17 |
| PBV / Sector |
3.39 / 7.44
|
| Earning Per Share | 2.01 |
| PE / Sector |
38.35 / 29.05
|
| PEG or PE/Growth / Sector |
-0.33 / 0.40
|
| Average 1M Daily Value |
46.91 M
GREAT
|
| Average 1W Daily Value |
46.39 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-10 09:44:00 |
| Symbol | LIVN |
| Name | LIVANOVA PLC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 54.93 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,109.03 / 18,471.99 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
Phone: 44 20 3325 0660
Website: https://www.livanova.com
Employees: 3,300
Sector: Healthcare >> Medical Devices
Description: LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
Google